Pyxis Oncology Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Source: Globenewswire
Stock Options Granted: Pyxis Oncology granted stock options to purchase 382,518 shares to seven new employees under the 2022 Inducement Plan, with options vesting over four years and a ten-year term at an exercise price of $2.22.
Company Focus and Development: Pyxis Oncology is developing next-generation antibody-drug conjugates for difficult-to-treat cancers, with its lead candidate, MICVO, currently in Phase 1 clinical studies targeting recurrent and metastatic head and neck squamous cell carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
